Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Reldesemtiv Shows Efficacy for Spinal Muscular Atrophy in PII: Astellas/Cytokinetics
October 9, 2018
- I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
October 5, 2018
- Fujifilm Develops New Technology to Search and Design Candidate Compounds Using Structural Formulas Alone
October 5, 2018
- Novo’s Oral GLP-1 Analogue Semaglutide Comparable to Subcutaneous Dulaglutide in No. of AEs: Japan PIIIa Study
October 5, 2018
- Blincyto OK Now in Hand, Amgen Astellas JV Revs Up for Foray into Japan Oncology Market
October 4, 2018
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
- Daiichi Sankyo/Kite’s CAR-T Cell Therapy Scoops Up Orphan Status for B-Cell Lymphoma
October 4, 2018
- Bavencio on Back Foot, but Merck KGaA Has High Hopes for Next-Gen I/O Therapy M7824
October 3, 2018
- Fujifilm, Taisho Detail Sales Schemes after Tie-Up Dissolution Next March
October 3, 2018
- Kaken Grants Distribution Rights for Efinaconazole to Main Life in Hong Kong, Macau
October 3, 2018
- Adcetris Improves PFS as Frontline Therapy for PTCL in PIII: Takeda/Seattle Genetics
October 3, 2018
- Ono to Transfer 5 Established Injectable Brands to Maruishi
October 2, 2018
- FDA OKs Pediatric Label Expansion for Fycompa: Eisai
October 2, 2018
- Alnylam Files Patisiran in Japan, Anticipates Nod in Mid-2019
October 2, 2018
- Astellas Seeks Approval for Japan’s 1st HIF-PH Inhibitor Roxadustat
October 2, 2018
- Wholesalers See “Some Reduction in Yakkasa” in Price Negotiations under New Guidelines: Will Reduction Continue?
October 2, 2018
- Maruho Licenses Cancer Stomatitis Treatment from NCC
October 2, 2018
- Konica Minolta Embarks on Precision Medicine Biz, Ex-GSK/AZ Exec Takes Helm
October 1, 2018
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- Maruho Takes Over Differin Gel Marketing Authorization from Galderma
October 1, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…